Amneal Pharmaceuticals Tidigare resultatutveckling
Tidigare kriterier kontrolleras 4/6
Amneal Pharmaceuticals har ökat intäkterna med en genomsnittlig årlig takt på 24.5%, medan Pharmaceuticals -branschen såg intäkterna växer på 12.2% årligen. Intäkterna har varit växande med en genomsnittlig takt på 9.3% per år. Amneal Pharmaceuticals s avkastning på eget kapital är 184.1% och den har en nettomarginal på 5%.
Viktig information
24.45%
Tillväxttakt i vinsten
25.15%
Tillväxttakt för EPS
| Pharmaceuticals Tillväxt i branschen | 5.95% |
| Intäkternas tillväxttakt | 9.29% |
| Avkastning på eget kapital | 184.06% |
| Nettomarginal | 5.05% |
| Senaste uppdateringen av resultatet | 30 Jun 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Aug 15
AMRX: Biosimilar And Generic Launches Will Drive The Next Leg Higher
Analysts have raised their price target on Amneal Pharmaceuticals to $25 from $23, citing a strong Q2 beat, an improved outlook, and the view that upcoming biosimilar and generic launches, along with a broader portfolio, could support higher long term revenue and margin assumptions in current models. Analyst Commentary Recent research on Amneal Pharmaceuticals points to increasingly constructive sentiment, with multiple bullish analysts lifting price targets following the strong Q2 report and updated guidance.Analysartikel • Aug 07
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) just reported healthy earnings but the stock price didn't move much...
Uppdatering av berättelse • Aug 01
AMRX: Crexont And Biosimilars Will Test Fairly Valued 2026 Outlook
Analysts have lifted their fair value estimate for Amneal Pharmaceuticals by $2.00 to $20.25, citing updated assumptions on revenue growth, profit margins, and future P/E that reflect recent price target increases related to Crexont, Women's Health, and biosimilar progress. Analyst Commentary Recent commentary on Amneal Pharmaceuticals focuses on how key growth drivers and execution on upcoming launches could influence valuation over the next few years.
Ny berättelse • Aug 01
Biosimilars And GLP-1 Expansion Will Expose Mounting Operational And Execution Risks
Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals develops, manufactures and markets affordable medicines across generics, biosimilars and specialty products in the United States and selected global markets. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jul 20
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism
Summary Amneal Pharmaceuticals has diversified beyond generics, driving margin expansion and improved financial health, but now trades near all-time highs. AMRX’s growth hinges on the Kashiv BioSciences acquisition, which is expected to add biosimilars and support management’s $4.25 billion 2030 revenue target. Despite improved operating leverage and reaffirmed 2026 guidance, persistent debt, settlement costs, and dilution from acquisitions cap free cash flow potential. My DCF analysis suggests AMRX is fully valued for management’s bullish projections; I maintain a neutral/Hold rating given limited upside and execution risks. Read the full article on Seeking AlphaNy berättelse • Jul 17
Biosimilars Expansion And Vertical Integration Will Reshape Long-Term Outlook
Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals focuses on affordable medicines across generics, specialty drugs and biosimilars, with a growing presence in large molecule therapies. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Jul 15
AMRX: Biosimilars And 2026 Execution Will Shape Fairly Valued Outlook
Analysts have raised their fair value estimate for Amneal Pharmaceuticals by $1 to $18.25, citing higher price targets from recent research, confidence in growth from Crexont, Women's Health and biosimilars, and support from improving expectations reflected in a modestly higher assumed future P/E multiple. Analyst Commentary Recent Street research on Amneal Pharmaceuticals highlights a mix of enthusiasm around growth drivers like Crexont, Women's Health and biosimilars, alongside a few areas where execution and valuation expectations could face tests.Analysartikel • Jun 21
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
Why Amneal Pharmaceuticals Stock Is On Investors’ Radar Amneal Pharmaceuticals (AMRX) has been drawing attention after a strong share price move over the past month and past 3 months, prompting investors to reassess what the current valuation implies. The stock recently closed at US$16.21, and available data shows it trades at a discount to one independent intrinsic value estimate. This may interest readers comparing Amneal to other US biopharmaceutical companies. See our latest analysis for...Uppdatering av berättelse • Jun 19
AMRX: Biosimilar Buildout And 2026 Execution Will Shape Fairly Valued Stock
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals up to $17.25 from $17.20, citing higher projected profit margins and renewed confidence in the 2026 outlook as the company works to narrow its valuation gap with peers and advance its biosimilar efforts. Analyst Commentary Recent research on Amneal Pharmaceuticals highlights a mix of optimism on the 2026 setup and some areas where investors may want to stay disciplined on execution and valuation.Uppdatering av berättelse • Jun 04
AMRX: Biosimilar Execution And 2026 Outlook Will Support Share Rebound
Analysts have inched their fair value estimate for Amneal Pharmaceuticals up from $17.00 to $17.20 and raised the price target to $16.00, citing stronger confidence in the fiscal 2026 outlook, a solid Q1 update, and an increasing focus on biosimilar opportunities compared with peers. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Q1 report as a key support for their higher fair value estimates, viewing the current execution as consistent with their fiscal 2026 expectations.Uppdatering av berättelse • May 04
AMRX: 2026 EBITDA Outlook Will Support Rebound After GRx Driven Pullback
Amneal Pharmaceuticals' consensus analyst price target has shifted to $17.00, with analysts citing solid Q4 results, strengthened FY26 EBITDA guidance and a reset future P/E assumption as support for this updated view. Analyst Commentary Recent research has focused on how Amneal Pharmaceuticals' updated FY26 guidance and Q4 performance feed into valuation, growth expectations and execution risk around that new US$17.00 price target.Uppdatering av berättelse • Apr 19
AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup
Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.Uppdatering av berättelse • Apr 02
AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup
Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.Uppdatering av berättelse • Mar 18
AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback
Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.Uppdatering av berättelse • Mar 04
AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup
Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.Uppdatering av berättelse • Feb 17
AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup
Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.Uppdatering av berättelse • Feb 03
AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook
Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.Uppdatering av berättelse • Jan 19
AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook
Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.Uppdatering av berättelse • Jan 05
AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.Uppdatering av berättelse • Dec 13
AMRX: Complex Generics Approvals Will Support Future Earnings Upside
Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.Analysartikel • Nov 30
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Despite an already strong run, Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shares have been powering on, with a gain...Uppdatering av berättelse • Nov 29
AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook
Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.Uppdatering av berättelse • Nov 15
AMRX: Sustained Outperformance Will Drive Future Earnings Confidence
Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.Analysartikel • Nov 14
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) recently posted some strong earnings, and the market responded positively...Uppdatering av berättelse • Nov 01
AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum
Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.Uppdatering av berättelse • Sep 17
Global Health Trends And Pipeline Launches Will Fuel Future Potential
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.
Ny berättelse • Mar 22
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Amneal Pharmaceuticals tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 30 Jun 26 | 3,118 | 157 | 572 | 176 |
| 31 Mar 26 | 3,046 | 122 | 547 | 184 |
| 31 Dec 25 | 3,019 | 72 | 527 | 186 |
| 30 Sep 25 | 2,935 | 6 | 509 | 206 |
| 30 Jun 25 | 2,853 | 3 | 490 | 203 |
| 31 Mar 25 | 2,830 | -13 | 482 | 191 |
| 31 Dec 24 | 2,794 | -117 | 477 | 191 |
| 30 Sep 24 | 2,680 | -184 | 457 | 183 |
| 30 Jun 24 | 2,598 | -175 | 451 | 163 |
| 31 Mar 24 | 2,495 | -169 | 440 | 165 |
| 31 Dec 23 | 2,394 | -84 | 430 | 164 |
| 30 Sep 23 | 2,386 | 10 | 423 | 160 |
| 30 Jun 23 | 2,312 | -2 | 410 | 169 |
| 31 Mar 23 | 2,272 | -135 | 403 | 182 |
| 31 Dec 22 | 2,212 | -130 | 400 | 196 |
| 30 Sep 22 | 2,139 | -132 | 395 | 206 |
| 30 Jun 22 | 2,122 | -134 | 386 | 204 |
| 31 Mar 22 | 2,098 | 2 | 373 | 206 |
| 31 Dec 21 | 2,094 | 11 | 366 | 202 |
| 30 Sep 21 | 2,067 | 14 | 353 | 203 |
| 30 Jun 21 | 2,058 | 9 | 345 | 199 |
| 31 Mar 21 | 1,987 | -17 | 339 | 192 |
| 31 Dec 20 | 1,993 | 91 | 327 | 180 |
| 30 Sep 20 | 1,880 | 62 | 316 | 175 |
| 30 Jun 20 | 1,739 | -194 | 297 | 168 |
| 31 Mar 20 | 1,679 | -199 | 283 | 171 |
| 31 Dec 19 | 1,626 | -362 | 290 | 188 |
| 30 Sep 19 | 1,727 | -339 | 287 | 197 |
| 30 Jun 19 | 1,825 | -67 | 298 | 202 |
| 31 Mar 19 | 1,834 | -69 | 287 | 204 |
| 31 Dec 18 | 1,663 | -21 | 228 | 194 |
| 30 Sep 18 | 1,459 | 155 | 184 | 180 |
| 30 Jun 18 | 1,237 | 149 | 136 | 179 |
| 31 Mar 18 | 1,083 | 168 | 106 | 176 |
| 31 Dec 17 | 1,034 | 168 | 109 | 171 |
| 30 Sep 17 | 1,039 | 54 | 113 | 171 |
| 31 Dec 16 | 1,018 | 207 | 119 | 179 |
| 31 Dec 15 | 866 | 169 | 110 | 137 |
Kvalitetsintäkter: AMRX har en stor engång förlust av $76.1M {1 månader till 30th June, 2026 1 månader) 30th June, 2026.
Växande vinstmarginal: AMRX s nuvarande netto vinstmarginaler (5%) är högre än förra året (0.1%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: AMRX har blivit lönsamt under de senaste 5 åren och ökat intäkterna med 24.5% per år.
Accelererande tillväxt: AMRX s intäktstillväxt under det senaste året ( 4562.6% ) överstiger sitt 5-åriga genomsnitt ( 24.5% per år).
Resultat vs industri: AMRX vinsttillväxt under det senaste året ( 4562.6% ) översteg Pharmaceuticals branschen 1%.
Avkastning på eget kapital
Hög ROE: Medan AMRX s avkastning på eget kapital ( 184.06% ) är utestående, är detta mått skevt på grund av deras höga skuldnivå.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/19 11:05 |
| Aktiekurs vid dagens slut | 2026/08/19 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Amneal Pharmaceuticals, Inc. bevakas av 20 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| David Buck | B. Riley Securities, Inc. |